 The number of drug-able tumor-specific molecular aberrations has grown substantially in the past decade, with a significant survival benefit obtained from biomarker matching therapies in several cancer types. Molecular pathology has become fundamental not only to inform on tumor diagnosis and prognosis but also to drive therapeutic decisions in daily practice. This article was authored by Ewan Armalone, Marco Lever, Peter J. B. Sabatini, and others.